In addition to their benefits on renal and cardiovascular outcomes including heart failure, post hoc analyses of large clinical trials demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors have favorable effect on anemia [7–9]. This evidence concerns the gene SLC5A2 and heart failure.